FDA Grants Priority Review Status Read More »

This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients Read More »

Cannabics Pharmaceuticals Inc. (OTCQB: CNBX) a world leader in personalized cannabinoid medicine focused on cancer and its side effects, today announced that it has entered into agreement with Wize Pharma, Inc. (OTCQB: WIZP), a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, and that has distribution rights of known medical formulae related to eye diseases. Read More »

The U.S. Food and Drug Administration (FDA) has approved Cablivi®(caplacizumab-yhdp) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults. Read More »

Wixela™ Inhub™ is the first FDA-approved therapeutically equivalent generic of ADVAIR DISKUS® (fluticasone propionate and salmeterol inhalation powder) for certain patients with asthma or chronic obstructive pulmonary disease (COPD) Read More »

Sunovion Pharmaceuticals Inc. (Sunovion) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the New Drug Application (NDA) for apomorphine sublingual film (APL-130277) to treat OFF episodes (the re-emergence or worsening of Parkinson’s symptoms otherwise controlled by medications) experienced by people living with Parkinson’s disease (PD). Read More »

Aquestive Therapeutics, Inc. (Nasdaq: AQST), a specialty pharmaceutical company, focused on developing and commercializing differentiated products to solve therapeutic problems, announced that the U.S. District Court for the District of New Jersey has granted a temporary restraining order (TRO) that enjoins Alvogen from initiating any launch activities related to its generic buprenorphine/naloxone sublingual film. Read More »

Gig Harbor, WA, location to host patient clinic and research laboratory on-site Read More »

Accomplished Medical Physicist will drive relevant activities related to Antibody Radiation Conjugates for targeted conditioning, therapeutic combinations, and AWE technology platform development Read More »

Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 pivotal trial Read More »

BIOC51 Antimicrobial Activity against Bacillus anthracis (Anthrax), Adding to the List of Bacteria Susceptible to the Company's Drug Candidate Read More »

Safe Rx announced its product availability in AmerisourceBergen, with merchandising kits available to all AmerisourceBergen California customers. Read More »

Comprised of an experienced leadership team, visionary investors, and renowned scientists in cell therapy, gene therapy, and gene editing Read More »

SOPHiA GENETICS, a leading health tech company, announced the closing of a $77 million investment round to accelerate the democratization of Data-Driven Medicine. Read More »

Teva Pharmaceutical Industries Ltd., (NYSE and TASE: TEVA) today announced the launch of a generic version of Elidel®1 (pimecrolimus) Cream, 1% in the U.S. Read More »

First and Only FDA-Approved Inhaled Levodopa for Intermittent Treatment of OFF Episodes in People with Parkinson’s Taking Carbidopa/Levodopa Read More »

Award Supports Advancement of BIOC51 Through Toxicology Studies in 2019 Read More »

Mylan achieves key milestone to provide U.S. diabetes patients with more affordable generic version of Sanofi's Lantus® insulin glargine vials Read More »

Fimbrion Therapeutics, Inc. announced that under its joint research collaboration with GSK, researchers have identified an orally available, small molecule development candidate for the treatment and prevention of urinary tract infections (UTIs). Read More »

Ensuring the safety of our nation’s drug supply is a cornerstone of our consumer protection mission. Read More »